Literature DB >> 18537555

Functional selectivity in GPCR modulator screening.

Terry Kenakin1.   

Abstract

In high throughput screening systems, a single concentration of a new compound is tested in a biological system to detect direct effects (agonists) or effects on other ligands (antagonists). In this latter case, the chemical context of the assay is defined by a balance of maximal sensitivity (limited agonist concentration) and maximal window to observe effect (sizable agonist concentration to induce measurable effect). For allosteric modulators, there are other factors that should be considered in high throughput screening environments. Specifically, the saturable aspect of allosteric effect can dissociate the observed ordinate change in response (% inhibition) and potency of effect (concentration at which a given ordinate % effect is obtained). Also, the specter of probe dependence can be important in systems where the physiologically relevant agonist cannot be used for screening (i.e. HIV-1 entry). Finally, the interactive nature of allosteric systems can cause complex relationships between the chemical context of an assay and potency of allosteric modulator. For example, in cases where the efficacy of an agonist is reduced but the affinity is increased by a modulator, it may be more beneficial to have higher concentrations of agonist in the screening assay to optimize sensitivity to modulators. This must be balanced for allosteric potentiators with the need to retain a window to observe increased agonist effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537555     DOI: 10.2174/138620708784534824

Source DB:  PubMed          Journal:  Comb Chem High Throughput Screen        ISSN: 1386-2073            Impact factor:   1.339


  16 in total

Review 1.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 2.  Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.

Authors:  Gregory J Digby; Jana K Shirey; P Jeffrey Conn
Journal:  Mol Biosyst       Date:  2010-06-25

Review 3.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 4.  Positive allosteric modulators to peptide GPCRs: a promising class of drugs.

Authors:  Tamas Bartfai; Ming-wei Wang
Journal:  Acta Pharmacol Sin       Date:  2013-04-29       Impact factor: 6.150

5.  Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening.

Authors:  Cassandra Koole; Denise Wootten; John Simms; Celine Valant; Rohan Sridhar; Owen L Woodman; Laurence J Miller; Roger J Summers; Arthur Christopoulos; Patrick M Sexton
Journal:  Mol Pharmacol       Date:  2010-06-14       Impact factor: 4.436

6.  Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7.

Authors:  Colleen M Niswender; Kari A Johnson; Nicole R Miller; Jennifer E Ayala; Qingwei Luo; Richard Williams; Samir Saleh; Darren Orton; C David Weaver; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2009-12-21       Impact factor: 4.436

7.  Distinct Signaling Patterns of Allosteric Antagonism at the P2Y1 Receptor.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Mol Pharmacol       Date:  2017-09-01       Impact factor: 4.436

Review 8.  DREADDs: novel tools for drug discovery and development.

Authors:  Hyeong-Min Lee; Patrick M Giguere; Bryan L Roth
Journal:  Drug Discov Today       Date:  2013-11-01       Impact factor: 7.851

9.  Age-Dependent Neuroimmune Modulation of IGF-1R in the Traumatic Mice.

Authors:  Hui Zhao; Xiaocong Zhao; Xiaoding Cao; Gencheng Wu
Journal:  Immun Ageing       Date:  2012-05-28       Impact factor: 6.400

Review 10.  Non-peptide agonists and positive allosteric modulators of glucagon-like peptide-1 receptors: Alternative approaches for treatment of Type 2 diabetes.

Authors:  Faisal Malik; Zhijun Li
Journal:  Br J Pharmacol       Date:  2021-04-19       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.